# LIBRETTO-001 (NCT03157128)

> A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03157128
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Non-Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Any Solid Tumor
- Interventions: LOXO-292
- Enrollment: 857
- Primary outcome: Phase 1: Maximum Tolerated Dose (MTD)
- Primary outcome: Phase 1: Recommended Phase 2 Dose (RP2D)
- Primary outcome: Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment

## Commentary we found

- X threads: 36
- Podcasts: 13
- YouTube: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=libretto-001-nct03157128

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03157128", "email": "<work email>"}; the inbox owner confirms by the emailed link.